Embecta Corp. (NASDAQ:EMBC) Short Interest Up 20.4% in February

Embecta Corp. (NASDAQ:EMBC - Get Free Report) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,650,000 shares, a growth of 20.4% from the January 31st total of 1,370,000 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average trading volume of 470,000 shares, the short-interest ratio is currently 3.5 days.

Analysts Set New Price Targets

EMBC has been the subject of a number of research reports. BTIG Research raised shares of Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price objective for the company in a research note on Wednesday, November 27th. Morgan Stanley upgraded shares of Embecta from an "underweight" rating to an "equal weight" rating and upped their price target for the company from $13.00 to $20.00 in a research report on Monday, December 2nd.

Insider Buying and Selling

In other news, Director Milton Mayo Morris sold 3,100 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the completion of the transaction, the director now directly owns 36,133 shares in the company, valued at approximately $591,858.54. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.42% of the stock is currently owned by insiders.

Remove Ads

Institutional Investors Weigh In On Embecta

A number of large investors have recently made changes to their positions in EMBC. Siemens Fonds Invest GmbH bought a new position in shares of Embecta during the fourth quarter valued at approximately $77,000. Ameriflex Group Inc. bought a new position in Embecta in the 4th quarter worth $53,000. Mackenzie Financial Corp lifted its position in shares of Embecta by 4.4% in the 4th quarter. Mackenzie Financial Corp now owns 40,956 shares of the company's stock worth $846,000 after purchasing an additional 1,743 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Embecta by 16.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 164,279 shares of the company's stock valued at $3,392,000 after purchasing an additional 23,611 shares in the last quarter. Finally, WBI Investments LLC purchased a new position in shares of Embecta during the fourth quarter valued at about $247,000. 93.83% of the stock is currently owned by institutional investors.

Embecta Trading Up 9.5 %

EMBC stock traded up $1.21 during midday trading on Monday, hitting $13.96. The company had a trading volume of 910,642 shares, compared to its average volume of 410,832. The stock has a market cap of $811.55 million, a price-to-earnings ratio of 13.96, a PEG ratio of 0.78 and a beta of 1.27. Embecta has a 52 week low of $9.93 and a 52 week high of $21.48. The stock's 50 day moving average price is $17.31 and its 200 day moving average price is $16.50.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Analysts predict that Embecta will post 2.85 earnings per share for the current year.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Shareholders of record on Friday, February 28th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.30%. The ex-dividend date of this dividend is Friday, February 28th. Embecta's payout ratio is 60.00%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.